Biomarker-Based Septic Shock Endotyping Strategy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for classifying pediatric septic shock patients into risk categories are complex and impractical for timely decision-making in critical care settings, lacking a simplified and effective biomarker-based strategy to differentiate between septic shock endotypes and guide appropriate treatments.
Innovation Solution
A biomarker-based endotyping strategy using a decision tree model with four genes (JAK2, LYN, PRKCB, and SOS2) to classify patients into high-risk or low-risk categories, allowing for personalized treatment approaches and monitoring therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a comprehensive biomarker-based endotyping strategy is used to accurately differentiate septic shock endotypes, then diagnostic precision and treatment guidance are improved, but the complexity of the classification method increases making it impractical for timely clinical decision-making
Solution Approach 1:
The comprehensive biomarker panel is segmented into a focused subset of four key genes (JAK2, LYN, PRKCB, SOS2) that capture the essential endotype differentiation. This segmentation maintains diagnostic precision by selecting the most discriminative markers while reducing overall complexity to a manageable level for clinical implementation.
Solution Approach 2:
The method extracts only the most critical biomarkers from a larger potential panel, isolating the four genes that provide the greatest discriminatory power for endotype classification. This extraction approach eliminates unnecessary complexity while preserving the essential diagnostic functionality needed for timely clinical decisions.
2Measurement precision
If multiple biomarkers are analyzed to improve risk stratification accuracy, then outcome prediction precision is improved, but the time required for analysis and decision-making increases
Solution Approach 1:
Rather than analyzing all potential biomarkers, the method applies partial action by focusing on exactly four key genes that provide sufficient discriminatory power for accurate risk stratification. This partial approach achieves the necessary precision for clinical decision-making without the time cost of comprehensive analysis of all available markers.
Solution Approach 2:
The method changes the parameter of biomarker quantity from a comprehensive panel to a specific subset of four genes. This parameter change optimizes the balance between analytical precision and time efficiency, allowing rapid processing while maintaining accurate endotype classification and risk prediction.
3Ease of operation
If a simplified biomarker panel is used to reduce analysis complexity and time, then ease of operation is improved, but the ability to differentiate between endotypes may be compromised
Solution Approach 1:
The method applies local quality by concentrating analytical resources on four specific genes with high discriminatory value rather than diluting effort across many markers. This focused approach ensures that the simplified panel maintains high endotype differentiation ability by selecting markers with superior local (individual) diagnostic quality.
Solution Approach 2:
The biomarker panel exhibits asymmetry in that not all genes are treated equally - instead of a balanced comprehensive panel, the method asymmetrically selects four genes with disproportionate discriminatory power. This asymmetric selection achieves both simplicity and high differentiation ability by weighting the panel toward the most informative markers.
Data Source
Figure 1
Figure 2
Figure 3a
AI summary
Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. In particular, the invention relates to identifying two or more biomarkers associated with septic shock in pediatric patients, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of two or more of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.